Rigel Pharmaceuticals (RIGL) Net Cash Flow (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Net Cash Flow of -$16.2 million for Q1 2026, down 47.51% year-over-year from -$30.8 million in Q1 2025, and down 103.28% quarter-over-quarter from -$8.0 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Net Cash Flow (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$16.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 47.51% year-over-year to -$16.2 million; the TTM figure through Mar 2026 stood at -$21.3 million (down 205.47% YoY), while the FY2025 annual figure was -$16.1 million, down 167.23% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$16.2 million, down from -$8.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $15.8 million in Q1 2023, with the low at -$16.2 million in Q1 2026.
- The 5-year median for Net Cash Flow is $2.5 million (2022), against an average of $328117.6.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 560.24% in 2024, then tumbled 257.38% in 2025.
- Rigel Pharmaceuticals' Net Cash Flow stood at -$5.4 million in 2022, then slumped by 133.55% to -$12.6 million in 2023, then jumped by 140.02% to $5.1 million in 2024, then sank by 257.38% to -$8.0 million in 2025, then slumped by 103.28% to -$16.2 million in 2026.
- Business Quant data shows RIGL's Net Cash Flow at -$16.2 million in Q1 2026, -$8.0 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 36.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.41 Mn |
| Jun 30, 2026 | 36.41 Mn |
| Mar 31, 2026 | -16.17 Mn |
| Mar 31, 2026 | -16.17 Mn |
| Dec 31, 2025 | -7.95 Mn |
| Dec 31, 2025 | -7.95 Mn |
| Sep 30, 2025 | -4.87 Mn |
| Sep 30, 2025 | -4.87 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Mar 31, 2025 | -10.96 Mn |
| Mar 31, 2025 | -10.96 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | 15.64 Mn |
| Sep 30, 2024 | 15.64 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Mar 31, 2024 | -7.21 Mn |
| Mar 31, 2024 | -7.21 Mn |